Diabetes Still Blunts Weight Loss, Even on the Newest Peptide Drug

People with type 2 diabetes lose less weight than everyone else on the same incretin drugs, and a new phase 3 trial of Eli Lilly's experimental triple-hormone peptide retatrutide just showed, in detailed numbers, exactly how much less.

The trial, called TRIUMPH-2, enrolled 1,152 adults with obesity and type 2 diabetes at 92 sites in eight countries, then randomized them to weekly retatrutide at 4 mg, 9 mg or 12 mg, or to placebo, for 80 weeks. At the top dose, participants lost an average of 20.8% of their body weight (49.6 lbs), against 4.0% on placebo, according to Lilly's own trial announcement and the peer-reviewed results published alongside it in The Lancet. More than half of the 12 mg group lost at least a fifth of their starting weight, and nearly 60% no longer met the clinical threshold for obesity by the end of the study, researchers reported in coverage from AJMC and Pharmacy Times. Blood sugar control improved alongside the weight loss: A1C fell by up to 1.6 percentage points, and about 40% of people on the two higher doses reached a non-diabetic A1C of under 5.7%, compared with 4.4% on placebo.

That 20.8% is a large number for a trial restricted to people with diabetes. It is also, on its own terms, the smaller of two numbers Lilly has now published for this drug. In retatrutide's original phase 2 trial, published in 2023 in the New England Journal of Medicine, people with obesity but no diabetes lost up to 24% of their body weight at 48 weeks — a result researchers at the time called unprecedented for a 48-week course. TRIUMPH-2's sister trial in non-diabetic participants, TRIUMPH-1, later reported 28.3% weight loss at 80 weeks and 30.3% at 104 weeks on the same 12 mg dose. Put the diabetic and non-diabetic results for the identical drug and dose side by side, and roughly a third of the expected weight loss is missing in the group with diabetes.

Why diabetes moves the needle

Retatrutide is built to activate three separate hormone receptors at once: the glucagon-like peptide-1 receptor (GLP-1R), the glucose-dependent insulinotropic polypeptide receptor (GIPR), and the glucagon receptor. GLP-1R slows digestion and signals fullness; GIPR adds an extra layer of insulin release and appears to improve how the body handles fat; the glucagon receptor nudges the liver to burn more energy. Earlier single-target drugs — Novo Nordisk's semaglutide works on GLP-1R alone, Eli Lilly's tirzepatide on GLP-1R and GIPR — produced smaller effects than this three-receptor approach, which is the whole rationale for building a triple agonist in the first place.

The diabetes gap traces mainly to one of those three receptors. GIP's ability to trigger insulin release depends on healthy insulin-producing beta cells, and chronic high blood sugar damages exactly that machinery. A 2020 review in the Journal of Clinical Endocrinology and Metabolism by Holst and Rosenkilde described this directly: prolonged beta-cell stress from hyperglycemia blunts the insulin-releasing side of GIP signaling through changes downstream of the receptor itself, not simply by switching the receptor off. In a non-diabetic trial participant, that pathway is intact; in someone who has lived with elevated blood sugar for years, it is already partly worn down before the drug's first dose. GLP-1R's appetite-suppressing effect is comparatively well preserved in diabetes, which is likely why some benefit survives even when the GIP-dependent portion doesn't.

What's solid, and what's still open

The weight and A1C numbers above come from a well-powered, randomized, double-blind, placebo-controlled trial — about as strong a design as clinical research gets, and large enough (1,152 people) to detect real differences between doses. That part is solid, though it's worth naming plainly that the trial was designed, run and paid for by Eli Lilly, the drug's maker, as is standard for registration-stage trials but still a detail worth keeping in view.

What the trial can't settle is how much of the diabetes/non-diabetes gap is biology versus something else. TRIUMPH-2's participants had lived with type 2 diabetes long enough to need treatment, and 92% were already on oral glucose-lowering medication — a population that, by definition, differs from a general obesity trial in ways beyond blood sugar alone: longer disease duration, different baseline metabolic damage, and background medications that can themselves affect weight. The trial also used two different ways of counting the result: the plainer "treatment-regimen" numbers above, and a stricter "treatment-policy" analysis that counts people who stopped the drug early as if they'd regained weight, which produced somewhat lower figures at the two higher doses. Side effects were the familiar incretin-drug list — diarrhea in around a quarter to a third of participants, nausea in 14% to 28%, generally described as mild to moderate — and 4% to 12% of people on the drug stopped because of them, versus 5% on placebo. None of this has been compared head-to-head against tirzepatide or semaglutide in the same diabetic population; the "roughly a third less" gap described above is a comparison across two separate trials of the same drug, not a controlled comparison between drugs. Lilly has said it plans to file for FDA approval in the first quarter of 2027, and approval would still turn on an FDA review of the complete safety record, not on these topline numbers alone.

What this means for researchers

The honest reading of TRIUMPH-2 is not "retatrutide failed people with diabetes" — 20.8% average weight loss in a diabetic population is, by the numbers released so far, higher than anything previously reported for an incretin therapy in this specific group. The honest reading is that the gap between diabetic and non-diabetic response, long observed with single- and dual-receptor drugs, has narrowed with a third receptor added but hasn't closed. That makes TRIUMPH-2 a useful data point for anyone modeling how much of incretin resistance in diabetes is receptor-specific rather than a blanket dampening of the whole pathway.

It also sharpens a specific open question for the field: whether a fourth mechanism, or a different ratio of agonism across the existing three receptors, could recover more of that missing third — or whether beta-cell damage from years of hyperglycemia is simply a harder ceiling than receptor engineering can lift. Eli Lilly presented a different approach to the same general problem at the same Milan meeting, pairing an amylin-receptor peptide with tirzepatide rather than adding a glucagon-receptor effect; Torrey Labs covered that combination trial separately. Readers who want background on how individual incretin and amylin peptides are classified can find it on Torrey Labs' compound library. Whichever mechanism wins out, the next trial to watch is the one that finally runs retatrutide, tirzepatide and a GLP-1/amylin combination against each other in the same diabetic population, head to head, rather than across separate studies years apart.